10-K
1
form10-k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
(Mark
One)
For
the fiscal year ended December 31, 2020
or
For
the transition period from __________to _____________
Commission
file number: 001-36199
PULMATRIX,
INC.
(Exact
name of registrant as specified in its charter)
99 Hayden Avenue, Suite 390
(Address of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code (781) 357-2333
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title of each class Name of each exchange on which registered
Common Stock, par value $0.0001 per share The NASDAQ Stock Market LLC
Securities
registered pursuant to Section 12(g) of the Exchange Act: None
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ]
No [X]
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes
[ ] No [X]
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes [X] No [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”,
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer [ ] Accelerated filer [ ]
Non-accelerated filer [X] Smaller reporting company [X]
Emerging Growth Company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [ ]
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No
[X]
Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. Yes [ ] No [X]
The
aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates computed by reference
to the price at which the common equity was last sold, as of June 30, 2020, the last business day of registrants most recently
completed second fiscal quarter, was $43,642,977.
As
of March 19,2021, the registrant had 56,249,062 shares of common stock outstanding.
DOCUMENTS
INCORPORATED BY REFERENCE
Specified
portions of Pulmatrix, Inc.’s Definitive Proxy Statement on Schedule 14A relating to the 2021 Annual Meeting of Stockholders
are incorporated by reference into PART III.
PULMATRIX,
INC.
TABLE
OF CONTENTS
Page No.
Forward-Looking Statements 1
PART I
Item 1. Business. 2
Item 1A. Risk Factors. 13
Item 1B. Unresolved Staff Comments. 28
Item 2. Properties. 28
Item 3. Legal Proceedings. 28
Item 4. Mine Safety Disclosures. 28
PART II
Item 6. Selected Financial Data. 29
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 38
Item 8. Financial Statements and Supplementary Data. 39
Item 9A. Controls and Procedures. 39
Item 9B. Other Information. 39
PART III
Item 10. Directors, Executive Officers and Corporate Governance 40
Item 11. Executive Compensation 40
Item 14. Principal Accounting Fees and Services 40
PART IV
Item 15. Exhibits, Financial Statement Schedules. 41
Signatures 45
i
PART
I
Forward-Looking
Statements
This
Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical fact contained
herein, including statements regarding our business plans or strategies, projected or anticipated benefits or other consequences
of our plans or strategies, projected or anticipated benefits from acquisitions to be made by us, or projections involving anticipated
revenues, earnings, or other aspects of our operating results, are forward-looking statements. Words such as “anticipates,”
“assumes,” “believes,” “can,” “could,” “estimates,” “expects,”
“forecasts,” “guides,” “intends,” “is confident that,” “may,” “plans,”
“seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions,
as well as statements in future tense, are intended to identify forward-looking statements. Forward-looking statements should
not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results
will actually be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s
good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual
performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important
factors that could cause such differences include, but are not limited to:
● our inability to carry out research, development and commercialization plans;
● termination of certain license agreements;
● adverse market and economic conditions;
● loss of one or more key executives or scientists; and
● difficulties in securing regulatory approval to market our product candidates.
For
a more detailed discussion of these and other risks that may affect our business and that could cause our actual results
to differentiate equally from those projected in these forward-looking statements, see the risk factors and uncertainties described
under the heading “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. The forward-looking statements
contained in this Annual Report on Form 10-K are expressly qualified in their entirety by this cautionary statement. We do not
undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date on which any
such statement is made or to reflect the occurrence of unanticipated events, except as required by law.
Unless
otherwise stated, references in this Annual Report on Form 10-K to “us,” “we,” “our,” or “Company”
refer to Pulmatrix, Inc., a Delaware corporation.
“iSPERSE”
is one of our trademarks used in this Annual Report on Form 10-K. Other trademarks appearing in this report are the property of
their respective holders. Solely for convenience, these and other trademarks, trade names and service marks referred to in this
report appear without the ®, TM and SM symbols, but those references are not intended to indicate, in any way,
we or the owners of such trademarks will not assert, to the fullest extent under applicable law, their rights to these trademarks
and trade names.
ITEM
1. BUSINESS.
Overview
We
are a clinical stage biotechnology company focused on the discovery and development of novel inhaled therapeutic products intended
to prevent and treat respiratory and other diseases with significant unmet medical needs.
We
design and develop inhaled therapeutic products based on our proprietary dry powder delivery technology, iSPERSETM
(inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to
the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with
highly efficient dispersibility and delivery to airways. iSPERSE powders can be used with an array of dry powder inhaler technologies
and can be formulated with a broad range of drug substances including small molecules and biologics. We believe the iSPERSE dry
powder technology offers enhanced drug loading and delivery efficiency that outperforms traditional lactose-blend inhaled dry
powder therapies. We believe the advantages of using the iSPERSE technology include reduced total inhaled powder mass, enhanced
dosing efficiency, reduced cost of goods and improved safety and tolerability profiles. We are developing iSPERSE-based therapeutic
candidates targeted at the prevention and treatment of a range of diseases, including allergic bronchopulmonary aspergillosis
(“ABPA”) in patients with asthma, and in patients with cystic fibrosis (“CF”), lung cancer, and in patients
suffering from neurological diseases such as acute migraine.
Corporate
History
We
were incorporated in 2013 as a Delaware corporation. Our resources are focused on the development of novel inhaled therapeutic
products intended to prevent and treat respiratory diseases and other diseases where inhaled drug delivery offers a potential
therapeutic advantage.
Business
Strategy
Our
goal is to develop breakthrough therapeutic products that are safe, convenient, and more efficient than the existing therapeutic
products for respiratory and other diseases where iSPERSE properties are advantageous.
The
iSPERSE technology may potentially improve upon the known efficacy and safety profile of currently available therapies.
Our current pipeline is aligned to this goal with the Pulmazole program for inhaled antifungal therapy to treat ABPA in patients
with asthma, the PUR3100 program for treatment of acute migraine, and the PUR1800 program, which has potential application in
both lung cancer and chronic obstructive pulmonary disease (“COPD”). All of these programs leverage improvements provided
by iSPERSE. We intend to capitalize on our iSPERSE technology platform and our expertise in inhaled therapeutics to identify new
product candidates for the prevention and treatment of diseases with significant unmet medical needs and to build our product
pipeline beyond our existing candidates. In order to advance clinical trials for our therapeutic candidates and leverage the iSPERSE platform to enable delivery of partnered compounds, we intend to form strategic
alliances with third parties, including pharmaceutical and biotechnology companies or academic or private research institutes.
We
expect to continue to incur significant expenses and operating losses for at least the next several years based on our drug development
plans. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities,
as we:
We
will continue to direct resources to advance the research and development of Pulmazole for ABPA in patients with asthma and CF.
In 2018, we successfully conducted clinical testing of Pulmazole in normal healthy volunteers and asthma patients. In 2019, we
began a Phase 2 study of Pulmazole with patients who have asthma and are suffering from ABPA but stopped the Phase 2 study due
to the COVID-19 pandemic and its impact on enrollment. In January 2021, we conducted a Type-C meeting with the U.S Food and Drug
Administration (“FDA”) to discuss our plans for a Phase 2b study. Utilizing the FDA feedback, we now intend to advance
Pulmazole into a Phase 2b efficacy study that will include a sixteen-week dosing regimen, rather than the four weeks dosing regimen
in the terminated Phase 2 study.
We completed preclinical safety
studies for our lead iSPERSE formulation in 2018 and advanced our formulation and process development efforts to support clinical
testing in stable moderate-severe COPD patients. In 2019, Pulmatrix entered into a License, Development and Commercialization
Agreement for PUR1800, an inhaled kinase inhibitor with Johnson & Johnson Enterprise Innovation, Inc. (“JJEI”).
In February 2021, we successfully dosed the first patient with PUR1800, in a Phase 1b study in patients with stable COPD. The
Phase 1b study data is anticipated in the fourth quarter 2021. JJEI retains an option for a worldwide license to develop and
commercialize PUR1800 and other kinase inhibitors as part of its Lung Cancer Initiative.
We
developed PUR3100, an iSPERSE formulation of DHE in 2020 and completed a pharmacokinetic study in dogs in January 2021. We will
continue to direct resources to advance the research and development of PUR3100 in treatment of acute migraine including completion
of preclinical safety studies in 2021 to enable a Phase 1/Phase 2 study start in Q1 2022.
To
add additional inhaled therapeutics to our discovery pipeline and facilitate additional discovery collaborations, we are leveraging
our iSPERSE technology and our management’s expertise in inhaled therapeutics and particle engineering to identify potential
product candidates. These potential product candidates are potentially safer and more effective than the current standard of care
for prevention and treatment of diseases with significant unmet medical needs.
The
status of our patent portfolio changes frequently in the ordinary course of patent prosecution. As of December 31, 2020, our patent
portfolio related to iSPERSE included approximately 112 granted patents, 16 of which are granted US patents, with expiration dates
from 2024 to 2034, and approximately 61 additional pending patent applications in the US and other jurisdictions. Our in-licensed
portfolio related to kinase inhibitors included approximately 241 granted patents, 31 of which are granted US patents, with expiration
dates from 2029 to 2035, and approximately 42 additional pending patent applications in the US and other jurisdictions. On
March 3, 2021 we filed a provisional patent application in the United States Patent and Trademark Office (“USPTO”) that discloses and claims certain formulations and methods
of use relevant to our PUR3100 program. We plan to file an international patent application under the patent cooperation treaty,
or PCT, based on the provisional patent application by the applicable deadline.
iSPERSE
Technology
We
use simple, safe excipients, including proprietary cationic salt formulations, to create a robust and flexible dry powder platform
technology that can accommodate a wide range of drug loads in highly dispersible particles. Our initial delivery platform emerged
from development of iCALMTM (inhaled Cationic Airway Lining Modulators), a non-steroidal anti-inflammatory therapy. The high
degree of aerosol efficiency and the density profile of our dry powder iCALM formulations provided the foundation for our development
of iSPERSE in 2012, which uses other monovalent and divalent salts.
iSPERSE
particles are engineered with a small, dense and dispersible profile to exceed the performance of traditional dry powder particles
as the iSPERSE particles have the dispersibility advantages of porous engineered particles. We believe this results in superior
drug delivery compared to traditional oral and injectable forms of treatment for certain respiratory diseases. Unlike lactose-blended
carrier formulations or low-density particles which disperse poorly, we believe that the iSPERSE technology platform offers several
potential benefits, achieved through the following technological innovations:
iSPERSE
particles can be engineered to include significantly less than one percent (1%) to greater than eighty percent (80%) active pharmaceutical
ingredients (“APIs”), which allows flexibility for dosing both high potency and high-drug load therapeutics.
● Superior flow rate independent lung delivery without carriers.
The
iSPERSE technology enables pulmonary delivery independent of lactose or other carriers, which results in significantly greater
lung dose at a matched nominal dose of conventional lactose-based formulations. iSPERSE formulations are dispersible across a
range of flow rates with consistent emitted dose and particle size. Performance across flow rates provides reliable dose delivery
across patient populations and reduces patient-to-patient variability.
● Delivery of macromolecules and biologics.
iSPERSE
powders can be used with an array of dry powder inhaler technologies and can be formulated with a broad range of therapeutic compounds
ranging from small molecules to proteins for both local and systemic drug delivery applications.
● Homogenous combinations of multiple drugs.
iSPERSE
creates homogenous particles including excipients and API, which allow for the consistent delivery of multiple APIs in a product.
We have successfully formulated iSPERSE-based products with dual and triple API combinations.
● Strong safety profile.
Current
iSPERSE products and planned clinical stage products to be formulated in iSPERSE are supported by robust preclinical safety profiles.
iSPERSE excipients include those with inhalation precedent and those that are generally regarded as safe (“GRAS”)
by other routes of administration.
Therapeutic
Candidates
Pulmazole
We
are developing iSPERSE-based inhaled formulations of anti-fungal drugs for the prevention and treatment of fungal infections and
allergic/hypersensitivity reactions to fungus in patients with severe lung disease, including those with asthma and CF. On January
28, 2020, Pulmazole received Fast Track designation from the FDA for the treatment of ABPA. Aspergillus colonization
and infections are likely underdiagnosed and occur frequently in patients of all ages. Colonization and infection with Aspergillus
spp. can lead to clinical disease with differing severities and complications depending on the immune status of the host.
Invasive aspergillosis is a frequently fatal disease that occurs in patients that are typically immune suppressed as a result
of treatment for hematologic cancers or immunosuppression prior to solid organ transplantation. In patients with asthma and CF,
Aspergillus can cause chronic infections that may be associated with worsening disease and larger declines in lung function
than patients without infection. A subset of patients with asthma and CF with Aspergillus colonization and/or infection
develop ABPA, which is a complex hypersensitivity reaction to fungal antigens. ABPA is a disease resulting in mucus production,
wheezing, pulmonary infiltrates, worsening bronchiectasis, and fibrosis of the lung.
In
patients with both asthma and CF, ABPA is commonly treated with oral steroids to treat inflammation and with oral antifungals
to reduce fungal infection. The inhalation administration of a drug affords direct delivery of the drug to the infected parts
of the lung, maximizing the dose to the affected sites and minimizing systemic exposure to the rest of the body where it could
cause significant side effects. Therefore, treatment of lung infections by direct administration of anti-infective products to
the lung may improve both the safety and efficacy of treatment compared to systemic administration by other routes, as well as
improving patient convenience as compared to oral and injectable forms of the treatment. We believe that local lung delivery by
inhalation of our iSPERSE formulation could provide convenient, effective and safe management of the debilitating and often life-threatening
lung infections that are not currently addressed by inhaled therapies.
Pulmazole
is our inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug that we are developing
to treat and prevent pulmonary fungal infections. Development of Pulmazole is focused on treatment of Aspergillus spp.
colonization and infection in patients with asthma and CF. In a Phase 1/1b clinical trial, Pulmazole appeared to be safe and well
tolerated in healthy normal volunteers (Parts 1 and 2) and in patients with asthma (Part 3). In Part 3 of the Phase 1/1b study,
following a single dose of Pulmazole, the pharmacokinetics (“PK”) analysis of sputum samples demonstrated ~70-fold
higher maximum lung concentration of itraconazole following inhalation of Pulmazole compared to oral Sporanox®
(Janssen Pharmaceuticals) despite inhaling only one tenth the dose of itraconazole (20 mg) relative to the dose of oral Sporanox
(200 mg). Lung exposure, as measured by sputum induction and analysis, was approximately 50-fold higher and plasma exposure was
approximately 85-fold lower following inhalation of 20 mg of Pulmazole compared to 200 mg of oral Sporanox. All endpoints
from the Phase 1/1b study were successfully met.
On
April 15, 2019, we entered into a Development and Commercialization Agreement (the “Cipla Agreement”) with Cipla Technologies
LLC (“Cipla”) for the co-development and commercialization, on a worldwide exclusive basis, of Pulmazole, our inhaled
iSPERSE drug delivery system enabled formulation of the antifungal drug, itraconazole, which is only available as an oral drug,
for the treatment of all pulmonary indications, including ABPA in patients with asthma. In July of 2019, we initiated a Phase
2 clinical study for Pulmazole. Due to delays in patient enrollment in the Phase 2 clinical study, exacerbated by the ongoing
COVID-19 pandemic, Cipla informed us that it desired to amend the Cipla Agreement. In connection with our renegotiation of the
Cipla Agreement, on July 10, 2020, the Pulmatrix/Cipla steering committee recommended the termination of the Phase 2 study due
the COVID-19 pandemic.
We
conducted a Type C meeting with the FDA on January 27, 2021 and leveraging the insights gained from this meeting, now plan to
commence the Phase 2b study when the risks of study conduct presented by the ongoing COVID-19 pandemic are
reduced to an acceptable level. The Phase 2b study design includes a 16-week dosing regimen as well as an exploration of potential
efficacy endpoints, whereas the terminated Phase 2 study comprised only a 4-week dosing regimen with safety and tolerability as
its primary endpoint. The longer dosing regimen of the planned new Phase 2b study is supported by the 6-month inhalation
toxicology study in dogs completed in April 2020.
In
addition to the planned new Phase 2b study, as part of the contemplated amendments to the Cipla Agreement, we may assign
to Cipla the exclusive rights to develop and commercialize Pulmazole in India, South Africa and other regional markets where
Cipla has strong clinical development and business capabilities. We have not agreed to any amendments to the Cipla Agreement as
of the date of the filing this Annual Report. However, we expect that discussions regarding amendments to the Cipla Agreement
will continue. No assurance can be given that we will be able to reach a mutually acceptable arrangement with Cipla for the conduct
of the Phase 2b clinical study in the future. Accordingly, if we are unable to agree with Cipla on such matters such as cost sharing
for the new study, we may be forced to suspend further development of Pulmazole.
Competition
and Market Opportunities
Current
treatments of pulmonary fungal infections highlight the limitations of oral or intravenous anti-infective treatments for lung
infections. Itraconazole is one of the most commonly prescribed therapies for treating Aspergillus spp. infections in patients
with asthma and CF. Itraconazole is available commercially as Sporanox in both a capsule and oral solution form. Itraconazole
is metabolized in the liver by CYP3A4 and coadministration with a large number of drugs is contraindicated due to the potential
for severe drug-drug interactions.
We
have demonstrated that Pulmazole achieves higher local lung itraconazole concentrations with significantly lower systemic exposure
relative to oral dosing, thus allowing for the potential to improve upon both the efficacy and safety profiles observed with oral
itraconazole. Furthermore, administration by inhalation significantly reduces the exposure of the drug in the rest of the body,
which may be beneficial in reducing systemic side effects and the risk of potentially toxic drug-drug interactions.
There
is precedent for both dry powder and nebulized inhaled anti-infective therapy to address specific pulmonary infections in patients
which demonstrates potential utility of inhaled drug delivery and market opportunity. Mylan currently markets TOBI Podhaler for
treatment of Pseudomonas aeruginosa infection in the United States and Forest Laboratories U.K. Limited (a subsidiary of
Actavis PLC) markets inhaled colistin, Colobreathe, for the same infection in Europe. Insmed currently markets Amikacin Liposome
Inhalation Suspension (Arikayce) in the United States for the treatment of lung disease caused by a group of bacteria, Mycobacterium
avium complex in a limited population of patients with the disease who do not respond to conventional treatment (refractory
disease). Arikayce is the first drug to be approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs,
or LPAD pathway, established by Congress under the 21st Century Cures Act to advance development and approval of antibacterial
and antifungal drugs to treat serious or life-threatening infections in a limited population of patients with unmet need. As required
for drugs approved under the LPAD pathway, labeling for Arikayce includes certain statements to convey that the drug has been
shown to be safe and effective only for use in a limited population. Arikayce was also approved under the Accelerated Approval
pathway. Under this approach, the FDA may approve drugs for serious or life-threatening diseases or conditions where the drug
is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients. The approval
of Arikayce was based on achieving three consecutive negative monthly sputum cultures by month six of treatment. Insmed was required
by the FDA to conduct an additional, post-market study to describe the clinical benefits of Arikayce. There are currently no products
specifically approved for treatment of ABPA, however, there are several inhaled anti-fungal agents currently in early stages
of development for invasive aspergillosis that could also have efficacy for ABPA.
New
methods to detect Aspergillus spp. infection in sputum have improved the sensitivity of diagnosis and clinical appreciation
for these infections. Pulmonary Aspergillus spp. infections affect approximately 14 million patients worldwide according
to the Global Action Fund for Fungal Infections (Improving Outcomes for Patients with Fungal Infections across the World: A Road
Map for the Next Decade). The majority of these cases occur in patients with asthma who have allergic disease and also include
invasive Aspergillus spp. infections that are associated with a high rate of mortality in immunocompromised patients. We
believe that Pulmazole compares favorably to the products discussed above and has the potential to generate significant value
based on treating and preventing pulmonary fungal infections in multiple patient populations.
Clinical
Development
Pulmazole
is our lead iSPERSE development program. We successfully completed a Phase 1/1b clinical study in 2018 which enabled us to initiate
a Phase 2 study in 2019, entitled: “A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate
the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult
Asthmatic Patients with ABPA. This study was terminated in July 2020 due to the ongoing impact of the COVID-19 pandemic on patient
enrollment and study conduct. The completion of a 6-month inhalation toxicology study in dogs in 2020 enables the conduct of a
Phase 2b study that will allow for a 16-week dosing regimen and exploration of potential endpoints. This study can be initiated
when conditions related to the COVID-19 pandemic are favorable with respect to study conduct and patient enrollment. For more
discussion of risks related to the COVID-19 pandemic, please see “Item 1A. RISK FACTORS.—Risks Related to Our Business—Business
interruptions could limit our ability to operate our business.
PUR1800
On
June 9, 2017, we entered into an exclusive, worldwide license agreement (the “RespiVert License Agreement”) with RespiVert
Ltd. (“RespiVert”), a wholly owned subsidiary of Janssen Biotech, Inc. (“Janssen”), and an affiliate of
JJEI, for access to a portfolio of novel drug candidates in a class called kinase inhibitors. The RespiVert License Agreement
terminates upon the expiration of the Company’s obligation to pay royalties for all licensed products, unless earlier terminated.
In addition, the RespiVert License Agreement may be terminated (i) by the Company for any reason upon 120 days’ advance
notice to RespiVert; (ii) by RespiVert upon receipt of notice from the Company of either voluntary or involuntary insolvency proceedings
of the Company; and (iii) by either party for a material breach which remains uncured following the applicable cure period.
We
successfully reformulated RV1162 into PUR1800. PUR1800 demonstrated the efficiency of the iSPERSE platform in non-clinical toxicology
results which showed a significant increased lung dose compared to earlier formulations of RV1162 and improved physical /chemical
stability of the product.
On
December 26, 2019, Pulmatrix entered into a License, Development and Commercialization Agreement with JJEI (the “JJEI License
Agreement”). Under the JJEI License Agreement, the Company has granted JJEI an option to acquire (1) the Company’s
rights to an intellectual property portfolio of materials and technology related to narrow spectrum kinase inhibitor compounds
and (2) an exclusive, worldwide, royalty bearing license to PUR1800.
In
February 2021, the first patient was dosed in a Phase 1b safety, tolerability and biomarker study that will enroll 15 patients
with stable moderate-severe COPD. The Phase 1b study will be randomized and double-blind and will include 14 days of daily dosing
with a 28 day follow up period. The COVID-19 pandemic could delay enrollment to the extent patients remain or become subject to
government “stay at home” mandates, patients feel like they cannot safely visit trial sites or patients drop out due
issues related to COVID-19.
Clinical
Development
Studies
conducted by RespiVert/Janssen for the small molecule formulated in PUR1800 (previously RV1162) demonstrated that the molecule
has been well tolerated for up to 14 days of dosing in patients with COPD. Analysis of sputum collected from patients with COPD
treated with RV1162 showed reduced levels of p38 phosphorylation in sputum cells and decreases in the number of neutrophils recovered
in sputum after 12 days of dosing. These findings suggest that inhalation of RV1162 may confer anti-inflammatory benefits after
a short dosing regimen.
The
ongoing Phase1b study of an iSPERSE formulation, PUR1800, in patients with stable moderate-severe COPD, is intended to show similar
results as the Phase 1/1b clinical study of RV1162 conducted by Janssen (Janssen Study EST001, ClinicalTrials.gov NCT01970618),
while demonstrating safety and tolerability of PUR1800 in patients with stable COPD. As we conduct the Phase 1b study of PUR1800,
we continue to assess the impact of the COVID-19 pandemic on our studies and current timeline. An increase of COVID-19 cases where
we are conducting the Phase 1b study may delay enrollment of patients and divert healthcare resources from our study. We cannot
predict the extent to which the COVID-19 pandemic may impact our clinical trials. However, it could result in a delay or indefinite
suspension of the trials. For more discussion of risks related to coronavirus, please see “Item 1A. RISK FACTORS.—Risks
Related to Our Business—Business interruptions could limit our ability to operate our business.
PUR5700
We
received access to PUR5700 (previously RV7031), a second novel drug candidate through the RespiVert License Agreement. On December
26, 2019, Pulmatrix entered into the JJEI License Agreement, pursuant to which the Company provided an assignment option to JJEI
of all the Company’s rights under the RespiVert License Agreement, to develop and commercialize PUR1800, PUR5700 and other
kinase inhibitors.
PUR3100
In
2020, Pulmatrix developed PUR3100, the iSPERSE formulation of DHE, for the treatment of acute migraine. Over 38 million people
suffer from migraine in the United States. Currently DHE is only available for intravenous infusion and therefore is not widely
used. If approved for commercialization, PUR3100 should be the first orally inhaled DHE treatment for acute migraine and be an
alternative to other acute therapies, such as oral and intravenous triptans that currently represent over 90% of the annual migraine
prescriptions in the United States. Given the oral inhaled route of delivery, PUR3100 is anticipated to provide a rapid onset
of migraine symptom relief with a favorable tolerability profile.
Competition and Market Opportunities
Current treatments for migraine include
oral, intranasal, intravenous (“IV”) or intramuscular (“IM”) formulations of triptans, dihydroergotamine,
and CGRP antagonists. Studies show that migraineurs are underdiagnosed, undertreated, and experience substantial decreases in
functioning and productivity, which in turn translates into diminished quality of life for individuals, and financial burdens
to both health-care systems and employers. All current treatments suffer from limited efficacy and/or tolerability and there exists
a significant unmet need for safe and effective alternatives to current treatments.
DHE has been shown to be effective in
the treatment of migraine and, in particular, hard to treat migraines, such as menstrual migraine, migraine upon awakening,
and severe migraine. Utilization of DHE has been limited due to its poor oral bioavailability, requiring IV or intranasal
dosing. IV dosing generally requires administration in a healthcare setting and the high exposure levels results in
significant nausea and emesis and as such has been limited to use only in patients with severe intractable migraine.
Intranasal dosing with Migranal (Bausch Health US LLC) has been poorly adopted due to poor exposure resulting in inconsistent
efficacy.
There is precedent for an inhaled DHE therapy.
MAP Pharmaceuticals, Inc. developed MAP0004, also known as Levadex or Semprana, a liquid suspension formulation of DHE, designed
to be dosed via a pMDI inhalation device. Their published data indicate a safe and well tolerated formulation with rapid onset
and long-lasting efficacy that compared very favorably to existing treatments. Development of MAP0004 led to a new drug application
(“NDA”) but was halted after several complete response letters from the FDA citing Chemistry, Manufacturing and Controls
(“CMC”) issues related to dose uniformity and stability issues. Regardless of the failure of MAP0004, the efficacy
and tolerability of the formulation reported by MAP Pharmaceuticals provides proof of concept for an inhaled DHE formulation.
PUR3100, the iSPERSE formulation planned by Pulmatrix is anticipated to deliver DHE to the lung with efficacy and tolerability
that compares favorably with MAP0004..
There are no other inhaled DHE formulations
currently in development. There are two intranasal formulations of DHE currently in development. Satsuma Pharmaceuticals have
developed a dry powder formulation of DHE for intranasal dosing and recently completed a Phase 3 study (ClinicalTrials.gov NCT03901482).
Despite failure of this study to achieve its primary endpoint, Satsuma have announced that development of this formulation will
continue, though no timeline for additional clinical studies has been announced. Impel Neuropharma is developing a formulation
of DHE based on the Migranal formulation with an improved POD delivery technology using a propellant to deliver the formulation
deep into the sinus cavity. Impel recently announced acceptance of their NDA by the FDA with a target Prescription Drug User Fee
Act (“PDUFA”) date of September 2021.
Clinical
Development
Pulmatrix
plans to conduct a 14-day GLP toxicology study in 2021 that will enable an Investigational New Drug (“IND”) filing
with FDA in Q1 2022. Following the filing of the IND, Pulmatrix plans to initiate a 2-part Phase 1/Phase 2 study
in patients with episodic migraine using the iSPERSE formulation PUR3100. This study will evaluate single dose PK, safety and
tolerability, and the effect of dose on a range of relevant clinical endpoints.
Business
Development
On April 15, 2019, Pulmatrix entered
into a Development and Commercialization Agreement (the “Cipla Agreement”) with Cipla Technologies LLC (“Cipla”)
for the co-development and commercialization, on a worldwide exclusive basis, of Pulmazole, our inhaled iSPERSE drug delivery
system enabled formulation of the antifungal drug, itraconazole. According to the agreement, Pulmatrix and Cipla share equally
product development and commercialization costs and free cash flow from worldwide commercialization from future sales of Pulmazole.
On
December 26, 2019, Pulmatrix entered into a License, Development and Commercialization Agreement with JJEI (the “JJEI License
Agreement”). Under the JJEI License Agreement, the Company has granted JJEI an option to acquire (1) the Company’s
rights to an intellectual property portfolio of materials and technology related to narrow spectrum kinase inhibitor compounds
and (2) an exclusive, worldwide, royalty bearing license to PUR1800 and PUR5700.
On
April 9, 2020, we entered into a Collaboration and License Agreement (the “Sensory Cloud Agreement”) with Sensory
Cloud, Inc. (“Sensory Cloud”). Under the terms of the Sensory Cloud Agreement, we have granted Sensory Cloud an exclusive,
worldwide, royalty bearing license to PUR003 and PUR006 (the “Sensory Licensed Product”), our proprietary aerosol
salt solution for delivery or administration to or through the nasal passages also known as NasoCalm, as well as related patents
and know-how, for use in the field. PUR003 and PUR006, were originally developed by the Company as potential anti-infective biodefense
medical countermeasure products. However, the Company decided to no longer develop these products and instead prioritized the
development of other programs. For purposes of the Sensory Cloud Agreement, the field means the formulation and commercialization
of over-the-counter products for the prophylaxis, prevention and treatment of upper and lower respiratory disease that are delivered
or administered to or through the nasal passages. The license granted to Sensory Cloud does not cover the development or commercialization
of any prescription products.
Intellectual
Property
Patents
and Patent Applications
We
protect our intellectual property by filing and advancing patent applications and maintaining granted patents on our iSPERSE platform
technology and in-licensed kinase inhibitors, which includes claims to compositions of matter and methods of use for our Pulmazole,
PUR1800 and PUR3100 programs, and PUR003 and PUR006, as well as, manufacturing processes, devices and packaging relevant to our
iSPERSE platform and product candidates.
The
status of our patent portfolio changes frequently in the ordinary course of patent prosecution. As of December 31, 2020, our patent
portfolio related to iSPERSE included approximately 112 granted patents, 16 of which are granted US patents, with expiration dates
from 2024 to 2034, and approximately 61 additional pending patent applications in the US and other jurisdictions. Our in-licensed
portfolio related to kinase inhibitors included approximately 241 granted patents, 31 of which are granted US patents, with expiration
dates from 2029 to 2035, and approximately 42 additional pending patent applications in the US and other jurisdictions. On
March 3, 2021 we filed a provisional patent application in the USPTO that discloses and claims certain formulations and methods
of use relevant to our PUR3100 program. We plan to file an international patent application under the patent cooperation treaty based on the provisional patent application by the applicable deadline.
There
can be no assurance that the patent applications will be granted. The term of individual patents depends upon the legal term of
the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from
the earliest date of filing a non-provisional patent application. In the United States, the patent term of a patent that covers
a FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for
the patent term lost during the FDA regulatory review process. The length of the patent term extension is related to the length
of time the drug is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total
of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. In the future,
if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products.
Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved
drug. We plan to seek patent term extensions to extend the patent coverage of any of our products that received regulatory approval
in any jurisdiction where these extensions are available. However, there is no guarantee that the applicable authorities, including
the FDA in the United States, will agree with our assessment on whether such extensions should be granted, and if granted, the
length of such extensions.
The
patent positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual
questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued,
and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for
any of our product candidates. We cannot predict whether the patent applications we are currently pursuing will issue as patents
in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from
competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.
Trade
Secrets
We
also rely on trade secret protection of our confidential and proprietary information, including the iSPERSE technology. Although
we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees,
consultants and others, third parties may independently develop substantially equivalent proprietary information and techniques
or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our
trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers
and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with
Pulmatrix. These confidentiality agreements provide that all confidential information concerning our business or financial affairs
developed or made known to the individual during the course of the individual’s relationship with us must be kept confidential
and not disclosed to third parties except in specific circumstances. Our confidentiality agreements with our employees also provide
that all inventions conceived by the employee in the course of employment with us or from the employee’s use of our confidential
information are our exclusive property.
Manufacturing
We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product
candidates. We have small-scale production capabilities and generally perform early process development for our product candidates
to produce the quantities necessary to conduct preclinical studies of our investigational product candidates. We do not have,
and do not currently plan to acquire or develop, the facilities or capabilities to manufacture bulk drug substance or filled drug
product for use in human clinical studies. We rely on contract manufacturing organizations (“CMOs”) and third-party
contractors to generate drug-loaded formulations and produce larger, pilot- scale amounts of drug substance and the drug product
required for our clinical studies. We expect to continue to rely on CMOs to manufacture drug substances and drug products under
the appropriate current Good Manufacturing Practices (“cGMP”) conditions to perform clinical studies for the foreseeable
future. We also contract with CMOs for the labeling, packaging, storage and distribution of investigational drug products. These
arrangements allow us to maintain a more flexible infrastructure while focusing our expertise on researching and developing our
products.
We
expect to continue to rely on contract manufacturers to produce sufficient quantities of our product candidates in accordance
with the appropriate cGMPs for the pertinent phase of clinical trials. cGMP compliance includes strict adherence to regulations
for quality control, quality assurance, and the maintenance of records and documentation. The manufacturing facilities that manufacture
our approved drug products, if any are approved in the future, must comply with the FDA’s cGMP regulation requirements and
have acquired FDA or other regulatory approval for the manufacturing of our commercial products. Our contract manufacturers may
also be subject to inspections of facilities by regulatory authorities to ensure compliance with applicable regulations. Contract
manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages
of qualified personnel. We have little or no direct control over our manufacturers’ compliance with these regulations and
standards. Failure to comply with applicable regulatory requirements may result in fines and civil penalties, suspension of production,
suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. These actions could have
a material impact on the availability of products.
Suppliers
We
also rely on third-party contract manufacturers to supply the APIs that are used to formulate our therapeutic candidates. We place
purchase orders with one contract manufacturer for the APIs required for Pulmazole and PUR1800, but there are many other potential
contract manufacturers that may be capable of manufacturing APIs for Pulmazole and PUR1800 or any of our other drug products in
the market. We additionally rely on third-party vendors to supply raw materials for our APIs and drug products.
Research
and Development
For
fiscal years ended December 31, 2020 and 2019, we spent approximately $15.6 million and $12.8 million, respectively on research
and development activities.
Government
Regulation
Pharmaceutical
companies are subject to extensive regulation by national, state and local agencies, such as the FDA, in the United States and
the European Medicines Agency in Europe. The manufacture, distribution, marketing, and sale of pharmaceutical products
are subject to government regulation in the United States and various foreign countries. Additionally, in the United States, we
must follow rules and regulations established by the FDA requiring the presentation of data indicating that our products are safe
and efficacious and are manufactured in accordance with cGMP regulations. If we do not comply with applicable requirements, we
may be fined, the government may refuse to approve our marketing applications or allow us to manufacture or market its products,
and we may be criminally prosecuted. We and our manufacturers and clinical research organizations may also be subject to regulations
under other federal, state and local laws, including, but not limited to, the U.S. Occupational Safety and Health Act, the Resource
Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations
of other countries. Pharmaceutical companies must ensure their compliance with the Foreign Corrupt Practices Act and federal healthcare
fraud and abuse laws, including the False Claims Act, and the U.S. government has increased its enforcement activity regarding
illegal marketing practices domestically and internationally.
These
regulatory requirements impact our operations and differ from one country to another, such that securing the applicable regulatory
approvals of one country does not imply the approval of another country. However, securing the approval of a more stringent body,
e.g. the FDA, may facilitate receiving the approval by a regulatory authority in a different country where the regulatory
requirements are similar or less stringent. The approval procedures involve high costs and are manpower intensive and usually
extend over many years and require highly skilled and professional resources.
FDA
Approval Process
The
steps required to be taken before a new drug may be marketed in the United States generally include:
● Completion of preclinical laboratory and animal testing;
● Submission and approval of a NDA.
Clinical
studies are conducted under protocols detailing, among other things, the objectives of the study, what types of patients may enter
the study, schedules of tests and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring
safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must
be submitted to the FDA as part of the IND application.
In